A Phase II Trial of Valproic Acid (Depakote ER ®) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive
PURPOSE: This phase II trial is studying how well valproic acid works in treating patients
with thyroid cancers that do not respond well to other treatments.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Decrease in thyroglobulin level and tumor size
16 months
No
Electron Kebebew, MD
Principal Investigator
University of California, San Francisco
United States: Institutional Review Board
Valproic Acid
NCT00525135
August 2007
March 2009
Name | Location |
---|---|
UCSF Comprehensive Cancer Center | San Francisco, California 94115 |